SDGR stock ripped 8% higher in after-hours trading on December 10, 2021, after the company released preclinical data on its MALT1 inhibitor program.
Schrödinger Reports Preclinical Data Supporting Advancement Of Its MALT1 Inhibitor Program At American Society Of Hematology 2021 Annual Meeting
NEW YORK–(BUSINESS WIRE)– Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today presented new preclinical data from its mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor program in B-cell lymphomas in a poster session at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia. MALT1 is considered a potential therapeutic target for several non-Hodgkin’s B-cell lymphomas as well as chronic lymphocytic leukemia. Schrödinger has identified novel MALT1 inhibitors that demonstrate strong anti-tumor activity across multiple tumor models, including cell- and patient-derived xenograft models, and combination potential with other agents, including standards of care such as ibrutinib.
- Data Highlight Strong Anti-Tumor Activity Across Multiple Tumor Models and Combination Potential with Other Agents
- On Track to Submit Investigational New Drug Application for MALT1 Development Candidate to the U.S. Food and Drug Administration in the first half of 2022
“We are pleased that our data strongly underscore the therapeutic potential of our MALT1 inhibitors and present an opportunity to advance a potential best-in-class MALT1 inhibitor into the clinic,” said Karen Akinsanya, Ph.D., executive vice president, chief biomedical scientist and head of discovery R&D at Schrödinger. “We are on track to submit the IND for our MALT1 development candidate to the FDA in the first half of 2022.”
The data presented suggest that targeting MALT1 may expand therapeutic options for patients with selected B-cell lymphomas, such as activated B-cell (ABC) subtype of diffuse large B cell lymphoma (DLBCL), with the possibility of expanding into other B-cell lymphomas such as mantle cell lymphoma (MCL). Furthermore, these small molecule MALT1 inhibitors demonstrate potential in combination with Bruton’s tyrosine kinase (BTK) inhibitors to overcome drug-induced resistance in patients with relapsed/refractory B-cell lymphomas.
The presentation, “Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies,” highlighted preclinical data with multiple lead molecules discovered using Schrodinger’s proprietary physics-based free energy perturbation (FEP+) modeling technology. These molecules demonstrate potent inhibition of MALT1 enzymatic activity and anti-proliferative activity in the ABC-DLBCL cell lines, such as OCI-LY3 and OCI-LY10. In combination with approved agents, these inhibitors demonstrate strong combination potential with Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib in ABC-DLBCL cell lines. In ABC-DLBCL cell line-derived xenograft (CDX) models, the company’s representative MALT1 inhibitor induces tumor regression as a single agent and complete tumor regression in combination with ibrutinib. The representative MALT1 inhibitor, when tested in LY2298 patient-derived xenograft (PDX) models, demonstrates similar results. In addition, the representative MALT1 inhibitor was explored in a CDX model derived from a mantle cell lymphoma REC-1 cell line, and demonstrates strong anti-tumor activity of ~78% tumor growth inhibition as a single agent. Taken together, these data strongly underscore the therapeutic potential of Schrödinger’s MALT1 inhibitors and support further evaluation of a potential best-in-class MALT1 inhibitor in clinical trials.
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries.
Schrodinger assumed at Equal Weight from Overweight at Morgan Stanley
On November 19, 2021, Morgan Stanley analyst Vikram Purohit downgraded Schrodinger to Equal Weight from Overweight with a price target of $49, down from $82, as he assumed coverage of the stock. While Purohit believes Schrodinger offers an “interesting mix” of a software business and a drug development pipeline, he sees upside potential in the near-to-mid term being constrained by the market’s focus on quarterly salesThe income statement provides a summary of a company's revenue and expenses over a specified period of time, typically a year or a quarter. It shows the company's total revenue, th... performance. He suspects investor sentiment may be difficult to gauge until investors gain comfort with 2022 sales guidance that is expected with Q4 earnings, the analyst added.
Schrödinger Awarded Grant to Accelerate Drug Discovery in Women’s Health
On November 18, 2021, Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it has been awarded a two-year, $4.9 million grant from the Bill & Melinda Gates Foundation to support a global women’s health initiative.
Schrödinger will receive $4.9 million research grant from the Bill & Melinda Gates Foundation to support early-stage drug discovery of non-hormonal contraceptives
The grant is part of a Gates Foundation initiative aimed at accelerating emerging opportunities to advance the field of contraceptive drug discovery. The emphasis of this initiative is to develop safe and effective, reversible, non-hormonal contraceptive agents with an improved overall tolerability and side effect profile compared to conventional (hormonal) methods. The goal is to empower women around the globe to take charge of their own health, enabling them to make informed decisions about family planning and have better access to contraceptive options that meet their needs.
“We are thrilled to be a part of this important drug discovery initiative that aims to provide an opportunity to remove barriers for women seeking contraceptive care around the globe,” said Karen Akinsanya, Ph.D., executive vice president, chief biomedical scientist and head of discovery research and development at Schrödinger. “This project is an example of Schrödinger’s commitment to global health as part of our broader environmental, societal and corporate social responsibility goals to support diversity, inclusiveness and improving opportunities for all.”
Schrödinger will leverage its computationally driven structure-based drug discovery platform to identify novel, high-affinity, selective small molecule leads for a specific ovarian protein during this initial project.
VIDEO Why Bill Gates Is Betting $500 Million On SDGR Stock
Daniel Pronk analyzed SDGR stock back in April 2021 and tried to figure out why Bill Gates is investing in this stock. Pronk writes, “I discuss why Bill Gates is investing over $500 million in Schrodinger stock (SDGR). Cathie Wood has also been investing heavily into Schrodinger (SDGR) and seems very bullish on the company. Both Bill Gates and Cathie continue to buy shares as well.”
SDGR Stock Technical Analysis
The short term trend is negative, as is the long term trend. There should be more interesting stocks out there. SDGR is one of the lesser performing stocks in the Health Care Technology industry. 66% of 49 stocks in the same industry do better. There is a positive divergence between large players volume and price which is bullish. There is a support zone ranging from 36.17 to 36.32. This zone is formed by a combination of multiple trend lines in multiple time frames. There are lots of resistance levels. There is resistance at 41.13 from a horizontal line in the daily time frame. There is resistance at 50.32 from a trend line in the weekly time frame. There is also resistance at 51.92 from a trend line in the weekly time frame. SDGR has a poor technical rating and the quality of the setup is also only medium at the moment. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first. Click here to sign up for email alerts on when SDGR stock is a good entry.
